Overview of Skin Cancers for General Practitioners

Tarek Haykal

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

Imaging Considerations for the Dermatologist

Masterclasses in Dermatology

C. Bakewell

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

How to Manage: Melanonychia

EADV 2022 Conference Coverage

M. Starace

Promoting Skin Self-Exam for the Secondary Prevention of Melanoma

David Polsky

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Winship Melanoma and Cutaneous Oncology Symposium

S. Patel

Increasing Melanoma Incidence with Unchanged Mortality, 1999 - 2019

Jesper Bo Nielsen

ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage I…

2024 ESMO Annual Meeting Insights Hub

H. Helgadottir

Year in Review: Surgical Treatment of Acral Melanoma

2023 Year in Review

M. Leventer

Top Risk Factors for Cancer by Sex and What to Do About It

MedCram

R. Seheult

Medical Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunothera…

2024 ASCO® Annual Meeting Insights Hub

H. Kluger